

Supporting Information

Visible-light-driven relay redox deracemization of cyclic sulfonamides catalyzed by a bifunctional chiral iridium complex

Table of Contents


1. General and Materials.....	S1
2. Synthesis of catalyst.....	S1
3. Intermediate MS.....	S2
4. Extra optimization of the reaction conditions.....	S2
5. General Procedure for deracemization of sulfonamides.....	S3
6. Synthesis of cyclic Sulfonamides 3.....	S3
7. Characterization data.....	S3
8. References.....	S7
9. Copies of NMR and HPLC.....	S7

1. General and Materials


General: All reactions were carried out under an atmosphere of air using the standard glass bottle, unless otherwise noted. ^1H NMR and ^{13}C NMR spectra were recorded at room temperature in CDCl_3 , $\text{DMSO}-d_6$ on 400 MHz instrument with tetramethylsilane (TMS) as internal standard. Enantiomeric excess was determined by HPLC analysis, using chiral column described below in detail. Optical rotations were measured by polarimeter. Flash column chromatography was performed on silica gel (200-300 mesh). All reactions were monitored by TLC analysis.

Materials: Commercially available reagents and solvents were used throughout without further purification. The catalysts Δ -IrS and Δ -IrO were prepared by following reported procedure¹. The racemic cyclic *N*-sulfonylimines were prepared according to the known procedures reported in the literature^{2,3}.


2. Synthesis of catalyst



5-(*tert*-butyl)-2-phenylbenzothiazole (197 mg, 0.74 mmol, 2 equiv.) was added to $\text{IrCl}_3 \cdot 3\text{H}_2\text{O}$ (130 mg, 0.37 mmol, 1 equiv.) in a mixture of 2-ethoxyethanol/water (3:1, 15 mL). The reaction mixture was heated at 130°C for 36 h under nitrogen. After the reaction was completed, the solvent was distilled off under reduced pressure. Add AgPF_6 (279 mg, 1.1 mmol, 3 equiv.) and 10 mL CH_3CN (distilled) to the schlenk flask. Immerse the schlenk flask in a preheated oil bath at 60°C for 14 h. Remove the schlenk flask from the oil bath and allow it to cool to room temperature. Filter off the solid and the filtrate was subjected to a flash silica gel chromatography ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{CN} = 30:1$, $R_f = 0.3$ in $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{CN} = 20:1$) to separate as yellow solids (300 mg, 0.31 mmol, 72% yield).




Add **S1** (250 mg, 0.26 mmol, 1 equiv.), Et_3N (126 mg, 1.25 mmol, 2.5 equiv.) and **S2** (116 mg, 0.53 mmol, 2 equiv.) in CH_2Cl_2 . Stir the reaction mixture for 4 h at room temperature. The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was subjected to a flash silica gel chromatography (PE/EA) to separate the two diastereomers. Use PE:EA (25:1) as the eluent until the first diastereomer Λ -**S3** (118 mg, 0.12 mmol, 47% yield) and then use PE:EA (10:1) to elute the second diastereomer Δ -**S3** (130 mg, 0.14 mmol, 52% yield).



A suspension of the iridium auxiliary complexes $\Delta\text{-S3}$ (160 mg, 0.17 mmol, 1 equiv.) and TFA (78 μL , 1 mmol, 6 equiv.) in CH_3CN (HPLC, 10 mL) was stirred for 30 minutes. Remove the volatiles in vacuo to obtain a yellow oil. Dissolve the yellow oil in 10 ml of CH_3CN and add NH_4PF_6 (554 mg, 3.4 mmol, 20 equiv.) in one portion. Stir at room temperature for another 30 min. The reaction mixture was concentrated to dryness and subjected to a flash silica gel chromatography (100% CH_2Cl_2 to $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{CN} = 30:1$, $R_f = 0.3$ in $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{CN} = 20:1$) to give the enantiopure catalysts $\Delta\text{-IrS}$ (106 mg, 0.11 mmol, 66%) as yellow solids.


3. Intermediate MS



16-electron intermediate MS

4. Extra optimization of the reaction conditions

Table S1 Oxidation reaction solvent screening^a




Entry ^{a,c}	Oxidant	Solvent	Yield ^b
1	air	MeCN	77%
2	air	DCM	81%
3	air	THF	76%
4	air	toluene	61%

5	air	acetone	58%
6	air	CHCl ₃	68%
7	air	1,4-dioxane	67%
8	air	CCl ₄	57%
9	air	DCE	>95%
10	air	DMSO	>95%
11	air	EA	>95%
12	air	DMF	>95%
13	None (in N ₂)	DMF	none


^aReaction conditions: (±)-**4a** (0.2 mmol), Δ-IrS (1 mol%), TMG (0.1 mmol), solvent (2 mL), 390 nm LED, 8h. ^bDetermined by ¹H NMR with 1,3,5-trimethoxybenzene as the internal standard; ^cNone of the raw materials have been reacted.

5. General procedure for deracemization of sulfonamides



Racemic sulfonamides **1** (0.2 mmol) were placed in a 10 mL glass bottle and then Δ-IrS (1 mol%), TMG (0.5 equiv.), DMF (2 mL) was added in air. After this, the solution was irradiated under stirring with 40 W 390nm LEDs (distance approx. 4 cm) at room temperature for 8 h. After the reaction is completed, HCOONH₄ (9 equiv) and H₂O (1 mL) are added to the system in air and heated at 60°C for 18 hours. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography on silica gel (PE/DCM = 1:4) to provide pure products. Enantiomeric excess was established by HPLC analysis. Absolute configuration of the products were assigned as *S* by comparing their optical rotation with the literature.


6. Synthesis of Cyclic Sulfonamides **3**



A mixture of **1b** (115 mg, 0.3 mmol), iodomethane (47 mg, 0.33 mmol), dried potassium carbonate (54 mg, 0.39 mmol), and 18-crown-6 (54 mg, 0.03 mmol) in dry acetone (2 mL) was stirred at room temperature under nitrogen for 56 h. The mixture was evaporated to dryness and purified by flash chromatography on silica gel (EtOAc) to afford product **S4** as a white solid (117 mg, yield: 97%). A mixture of **S4** (55 mg, 0.137 mmol) and 3 mol/L HCl (137 μL, 0.417 mmol) in MeOH (3 mL) was stirred at room temperature for 2 h. The mixture was evaporated to dryness and purified by flash chromatography on silica gel (EtOAc) to afford product **3** as a white solid (36 mg, yield: 87%).


7. Characterization Data

(*S*)-3-phenyl-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**1a**): 97% yield, 96% ee(*S*), known compound⁴, white solid, m.p.= 134-135°C, [α]²⁰_D = +81.1 (c 0.46, CH₂Cl₂) [lit.⁴ [α]²⁵_D = +85.2 (c 0.5, CH₂Cl₂), 90% ee (*S*)]. ¹H NMR (400 MHz, CDCl₃) δ 7.88–7.83 (m, 1H), 7.61–7.53 (m, 2H), 7.40 (d, *J* = 1.8 Hz, 5H), 7.20–7.13 (m, 1H), 5.74 (d, *J* = 3.8 Hz, 1H), 5.06 (d, *J* = 3.8 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 139.9, 138.8, 134.7, 133.4, 129.5, 129.3, 129.0, 127.6, 125.4, 121.1, 77.4, 77.1, 76.8, 61.4. HPLC: Chiracel OJ column,




220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 20.6 min (maj) and 22.5 min.


(S)-3-3-(((tert-butylidimethylsilyloxy)methyl)phenyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1b): 66% yield, 91% ee(*S*), known compound^{4a}, colorless oil, $[\alpha]_D^{20} = +60.9$ (c 0.96, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.79 (m, 1H), 7.67 – 7.49 (m, 2H), 7.45 – 7.31 (m, 3H), 7.26 (d, *J* = 6.5 Hz, 1H), 7.19 – 7.12 (m, 1H), 5.74 (d, *J* = 4.0 Hz, 1H), 5.02 (d, *J* = 4.1 Hz, 1H), 4.75 (s, 2H), 0.93 (s, 9H), 0.10 (d, *J* = 2.2 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 142.7, 139.9, 138.8, 134.8, 133.3, 129.5, 129.2, 126.6, 126.2, 125.5, 125.1, 121.1, 64.6, 61.4, 26.0, 18.4, -5.2. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.8 mL/min, retention time 7.4 min (maj) and 9.0 min.




(S)-3-(*m*-tolyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1c): 97% yield, 92% ee(*S*), known compound^{4b}, white solid, m.p. = 124–126 °C, $[\alpha]_D^{20} = +71.0$ (c 0.44, CH₂Cl₂) [lit.⁴ $[\alpha]_D^{20} = +96.1$ (c 0.28, CH₂Cl₂), 89% ee (*S*)]. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (t, *J* = 6.1 Hz, 1H), 7.55 (d, *J* = 15.1 Hz, 2H), 7.26 (d, *J* = 7.1 Hz, 1H), 7.17 (d, *J* = 7.8 Hz, 4H), 5.68 (s, 1H), 5.32 (s, 1H), 2.35 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 140.0, 139.1, 138.8, 134.7, 133.3, 129.8, 129.4, 129.1, 128.1, 125.4, 124.7, 121.1, 77.5, 77.1, 76.8, 61.4, 21.4. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 1.0 mL/min, retention time 10.8 min and 12.0 min (maj).




(S)-3-(*p*-tolyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1d): 95% yield, 92% ee(*S*) known compound^{4b}, white solid, m.p. = 169–171 °C, $[\alpha]_D^{20} = +58.1$ (c 0.58, CH₂Cl₂) [lit.⁴ $[\alpha]_D^{20} = +66.5$ (c 0.52, CH₂Cl₂), 90% ee (*S*)]. ¹H NMR (400 MHz, CDCl₃) δ 7.90–7.71 (m, 1H), 7.54 (qt, *J* = 6.7, 3.5 Hz, 2H), 7.31–7.23 (m, 2H), 7.19 (d, *J* = 7.7 Hz, 2H), 7.14 (d, *J* = 7.3 Hz, 1H), 5.69 (s, 1H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 140.2, 139.0, 135.8, 134.8, 133.3, 129.9, 129.4, 127.6, 125.4, 121.1, 77.4, 77.1, 76.8, 61.2, 21.2. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 20.2 min and 22.8 min (maj).




(S)-3-(3,5-dimethylphenyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1e): 93% yield, 95% ee(*S*), known compound⁶, white solid, m.p. = 204.5–206 °C, $[\alpha]_D^{20} = +74.1$ (c 0.45, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.93–7.74 (m, 1H), 7.54 (q, *J* = 7.7, 6.3 Hz, 2H), 7.16 (d, *J* = 6.4 Hz, 1H), 6.99 (d, *J* = 11.6 Hz, 3H), 5.65 (d, *J* = 3.2 Hz, 1H), 5.26–4.92 (m, 1H), 2.31 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 140.1, 139.0, 138.61, 134.8, 133.3, 130.7, 129.4, 125.4, 125.3, 121.1, 77.4, 77.1, 76.8, 61.4, 21.3. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.6 mL/min, retention time 17.5 min and 19.6 min (maj).




(S)-3-(3-isopropylphenyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1f): 99% yield, 93% ee(*S*), unknown compound, colorless liquid, $[\alpha]_D^{20} = +56.1$ (c 1.00, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 6.9 Hz, 1H), 7.54 (m, *J* = 6.1 Hz, 2H), 7.31 (t, *J* = 7.5 Hz, 1H), 7.25 (d, *J* = 9.1 Hz, 2H), 7.17 (t, *J* = 7.1 Hz, 2H), 5.72 (s, 1H), 5.30 (s, 1H), 2.92 (m, *J* = 6.9 Hz, 1H), 1.26 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 149.8, 140.1, 139.1, 134.5, 133.3, 129.4, 129.2, 126.8, 125.8, 125.5, 125.0, 120.9, 77.8, 77.5, 77.2, 61.4, 34.0, 24.0, 24.0. HRMS Calculated for C₁₆H₁₈NO₂S [M+H]⁺ 288.1053, found: 288.1053. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 15.0 min and 21.4 min (maj).



(S)-3-(4-ethylphenyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1g): 90% yield, 87% ee(*S*), known compound⁷, white solid, m.p. = 123–124 °C, $[\alpha]_D^{20} = +81.7$ (c 0.61, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.95–7.74 (m, 1H), 7.65–7.39 (m, 2H), 7.29 (d, *J* = 8.1 Hz, 2H), 7.23 (d, *J* = 7.9 Hz, 2H), 7.17 (d, *J* = 8.4 Hz, 1H), 5.71 (s, 1H), 4.99 (s, 1H), 2.67 (q, *J* = 7.6 Hz, 2H), 1.25 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 145.4, 140.1, 136.0, 134.8, 133.4, 129.4, 128.8, 127.7, 125.5, 121.1, 61.2, 28.6, 15.5. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.6 mL/min, retention time 43.9 min (maj) and 50.3 min.



(S)-3-(4-(tert-butyl)phenyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (1h): 73% yield, 99% ee(*S*), known compound⁶, white solid, m.p. = 145.1–146.2 °C, $[\alpha]_D^{20} = +63.3$ (c 0.15, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, *J* = 7.1 Hz, 1H), 7.55 (t, *J* = 5.9 Hz, 2H), 7.41 (d, *J* = 8.1 Hz, 2H), 7.30 (d, *J* = 8.2 Hz, 2H), 7.18 (d, *J* = 7.2 Hz, 1H), 5.73 (s, 1H), 1.32 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 152.2, 140.1, 135.7, 134.9, 133.3, 129.4, 127.4, 126.2, 125.5, 121.1, 77.4, 77.1, 76.8, 61.2, 34.7, 31.3. HPLC: Chiracel




AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.6 mL/min, retention time 12.8 min (maj) and 14.9 min.


(S)-3-(4-butylphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1i): 82% yield, 88% ee(*S*), unknown compound, white solid, m.p.= 87-89.4 °C, $[\alpha]_D^{20} = +68.2$ (c 0.5, CH₃Cl). ¹H NMR (400 MHz, CDCl₃) δ 7.80 (t, *J* = 6.6 Hz, 1H), 7.54 (q, *J* = 6.7, 6.2 Hz, 2H), 7.27 (d, *J* = 7.9 Hz, 2H), 7.17 (dd, *J* = 16.0, 7.3 Hz, 3H), 5.70 (s, 1H), 5.32 (s, 1H), 2.61 (t, *J* = 7.8 Hz, 2H), 1.60 (q, *J* = 7.4 Hz, 2H), 1.37 (m, *J* = 8.3, 7.3 Hz, 2H), 0.94 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 144.0, 140.1, 136.0, 134.7, 133.3, 129.4, 129.2, 127.6, 125.5, 121.1, 77.5, 77.2, 76.9, 61.2, 35.4, 33.5, 22.4, 14.0. HRMS Calculated for C₁₇H₂₀NO₂S [M+H]⁺ 302.1209, found: 302.1209. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.8 mL/min, retention time 10.3 min (maj) and 15.4 min.




(S)-3-(3,5-di-*tert*-butylphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1j): 86% yield, 62% ee(*S*), unknown compound, white solid, m.p.= 160.6-162.8 °C, $[\alpha]_D^{20} = +68.9$ (c 0.27, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.93–7.74 (m, 1H), 7.54 (q, *J* = 7.7, 6.3 Hz, 2H), 7.16 (d, *J* = 6.4 Hz, 1H), 6.99 (d, *J* = 11.6 Hz, 3H), 5.65 (d, *J* = 3.2 Hz, 1H), 5.26–4.92 (m, 1H), 2.31 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 152.0, 140.3, 137.8, 135.1, 133.2, 129.3, 125.4, 123.1, 121.7, 121.1, 77.4, 77.1, 76.8, 62.1, 35.0, 31.4. HRMS Calculated for C₂₁H₂₈NO₂S [M+H]⁺ 358.1835, found: 358.1835. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 90/10, flow = 0.7 mL/min, retention time 11.1 min and 12.5 min (maj).




(S)-3-(3-methoxyphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1k): 84% yield, 81% ee(*S*), known compound⁶, white solid, m.p.= 116.7-118.1 °C, $[\alpha]_D^{20} = +54.8$ (c 0.2, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.88–7.82 (m, 1H), 7.57 (t, *J* = 3.6 Hz, 2H), 7.33 (t, *J* = 8.2 Hz, 1H), 7.19 (d, *J* = 8.1 Hz, 1H), 7.04–6.86 (m, 3H), 5.71 (s, 1H), 5.02 (s, 1H), 3.80 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.2, 140.4, 139.7, 134.6, 133.3, 130.3, 129.5, 125.4, 121.1, 119.7, 114.5, 113.0, 77.5, 77.1, 76.8, 61.2, 55.4. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.7 mL/min, retention time 22.1 min and 30.5 min (maj).




(S)-3-(4-methoxyphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1l): 57% yield, 89% ee(*S*), known compound^{4b}, white solid, m.p.= 151-154 °C, $[\alpha]_D^{20} = +32.7$ (c 0.33, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.87–7.74 (m, 1H), 7.54 (q, *J* = 7.3, 6.2 Hz, 2H), 7.27 (d, *J* = 8.8 Hz, 2H), 7.18–7.10 (m, 1H), 6.90 (d, *J* = 8.7 Hz, 2H), 5.68 (d, *J* = 2.4 Hz, 1H), 5.14 (s, 1H), 3.81 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.1, 140.3, 135.0, 133.3, 130.7, 129.4, 129.0, 125.4, 121.1, 114.6, 77.4, 77.1, 76.8, 61.0, 55.4. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.8 mL/min, retention time 24.9 min (maj) and 38.2 min.




(S)-3-(3,5-dimethoxyphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1m): 71% yield, 87% ee(*S*), known compound^{4c}, white solid, m.p.= 167-168 °C, $[\alpha]_D^{20} = +71.5$ (c 0.35, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 6.7 Hz, 1H), 7.53 (q, *J* = 7.0 Hz, 2H), 7.20 (d, *J* = 6.7 Hz, 1H), 6.53 (d, *J* = 2.2 Hz, 2H), 6.42 (t, *J* = 2.3 Hz, 1H), 5.63 (s, 1H), 5.44 (s, 1H), 3.75 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 152.0, 140.3, 137.8, 135.1, 133.2, 129.3, 125.4, 123.1, 121.7, 121.1, 77.4, 77.1, 76.8, 62.1, 35.0, 31.4. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 26.3 min (maj) and 30.8 min.




(S)-3-(3-fluorophenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1n): 76% yield, 91% ee(*S*), known compound⁶, white solid, m.p.= 113-118 °C, $[\alpha]_D^{20} = +74.0$ (c 0.25, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 6.9 Hz, 1H), 7.56 (p, *J* = 7.4 Hz, 2H), 7.44–7.29 (m, 1H), 7.25–6.98 (m, 4H), 5.75 (d, *J* = 3.1 Hz, 1H), 5.58 (d, *J* = 4.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 161.8, 141.5, 139.1, 134.4, 133.5, 130.8, 129.7, 125.3, 123.2, 121.2, 116.1, 114.6, 77.4, 77.1, 76.8, 60.6. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.6 mL/min, retention time 23.5 min and 31.3 min (maj).




(S)-3-(4-fluorophenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1o): 94% yield, 92% ee(*S*), known compound⁵, white solid, m.p.= 163-167 °C, $[\alpha]_D^{20} = +84.6$ (c 0.46, CH₂Cl₂). [lit.⁴ $[\alpha]_D^{20} = +66.9$ (c 0.76, CH₂Cl₂), 85% ee (*S*)]. ¹H NMR (400 MHz, CDCl₃) δ 7.91–7.77 (m, 1H), 7.66–7.52 (m, 2H), 7.37 (dd, *J* = 8.5, 5.3 Hz, 2H), 7.22–6.97 (m, 3H), 5.74 (s, 1H), 5.14 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 164.3, 161.8, 139.6, 134.7, 133.5, 129.7, 129.5, 129.4, 125.3, 121.2, 116.4, 116.1, 60.6, 53.5. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 12.8 min (maj) and 19.3 min.




(S)-3-(3-chlorophenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1p): 79% yield, 95% ee(*S*), known compound⁸, white solid, m.p.= 137-138 °C, $[\alpha]_D^{20} = +101.15$ (c 0.29, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.92–7.79 (m, 1H), 7.70–7.51 (m, 2H), 7.49–7.29 (m, 4H), 7.24–7.11 (m, 1H), 5.72 (s, 1H), 5.31 (d, *J* = 6.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 140.8, 139.0, 135.1, 134.5, 133.6, 130.6, 129.8, 129.3, 127.6, 125.8, 125.3, 121.3, 77.4, 77.1, 76.8, 60.6. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 16.1 min (maj) and 20.6 min.




(S)-3-(4-chlorophenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1q): 85% yield, 88% ee(*S*), known compound⁵, white solid, m.p.= 179-181 °C, $[\alpha]_D^{20} = +83.2$ (c 0.25, CH₂Cl₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.66 (s, 1H), 7.88 (d, *J* = 7.0 Hz, 1H), 7.71–7.55 (m, 2H), 7.53–7.41 (m, 4H), 7.30 (d, *J* = 7.5 Hz, 1H), 5.92 (s, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 140.1, 140.0, 135.2, 133.7, 133.3, 130.1, 129.4, 129.2, 126.0, 121.1, 59.5, 40.6, 40.4, 40.2, 40.0, 39.8, 39.6, 39.4. HPLC: Chiracel OJ column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.7 mL/min, retention time 25.0 min (maj) and 29.7 min.




(S)-3-(4-phenoxyphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1r): 79% yield, 92% ee(*S*), unknown compound, white solid, m.p.= 101.5-104.8 °C, $[\alpha]_D^{20} = +44.2$ (c 0.5, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, *J* = 7.4 Hz, 1H), 7.57 (p, *J* = 7.2 Hz, 2H), 7.45–7.29 (m, 4H), 7.17 (q, *J* = 7.4 Hz, 2H), 7.01 (dd, *J* = 15.6, 8.3 Hz, 4H), 5.74 (s, 1H), 5.31 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 158.1, 156.5, 139.9, 134.8, 133.4, 133.3, 130.0, 129.6, 129.2, 125.5, 123.9, 121.1, 119.4, 119.0, 77.5, 77.2, 76.8, 60.8. HRMS Calculated for C₁₉H₁₆NO₃S [M+H]⁺ 338.0845, found: 338.0845. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.6 mL/min, retention time 30.9 min (maj) and 38.4 min.




(S)-3-(naphthalen-2-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1s): 92% yield, 96% ee(*S*), known compound⁵, white solid, m.p.= 191.2-192.4 °C, $[\alpha]_D^{20} = +127.0$ (c 0.37, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 8.06–7.74 (m, 5H), 7.53 (d, *J* = 4.2 Hz, 4H), 7.38 (d, *J* = 8.6 Hz, 1H), 7.13 (s, 1H), 5.87 (s, 1H), 5.34 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 139.7, 136.0, 134.7, 133.5, 133.4, 133.1, 129.6, 129.5, 128.1, 127.9, 127.2, 126.8, 126.8, 125.5, 124.5, 121.2, 77.4, 77.1, 76.8, 61.5. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.7 mL/min, retention time 30.4 min and 38.7 min (maj).




(S)-3-(benzofuran-5-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (1t): 86% yield, 88% ee(*S*), unknown compound, white solid, m.p.= 140-143.1 °C, $[\alpha]_D^{20} = +96.3$ (c 0.59, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.92–7.72 (m, 1H), 7.71–7.57 (m, 2H), 7.57–7.39 (m, 3H), 7.31–7.19 (m, 1H), 7.17–7.04 (m, 1H), 6.75 (d, *J* = 2.2 Hz, 1H), 5.82 (s, 1H), 5.47 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 155.0, 146.1, 140.3, 134.6, 133.5, 133.4, 129.5, 128.1, 125.5, 123.8, 121.1, 120.7, 112.2, 106.7, 77.5, 77.2, 76.9, 61.5. HRMS Calculated for C₁₅H₁₂NO₃S [M+H]⁺ 286.0532, found: 286.0532. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.8 mL/min, retention time 38.0 min (maj) and 49.9 min.



(S)-5-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (2a): 98% yield, 92% ee(*S*), known compound^{4d}, white solid, m.p.= 171-172 °C, $[\alpha]_D^{20} = +63.8$ (c 0.5, CH₃Cl). ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J* = 8.0 Hz, 1H), 7.39 (m, *J* = 2.4 Hz, 5H), 7.33 (d, *J* = 7.5 Hz, 1H), 6.92 (s, 1H), 5.69 (d, *J* = 4.1 Hz, 1H), 5.20 (s, 1H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 144.4, 140.2, 139.0, 132.1, 130.5, 129.2, 129.0, 127.6, 125.5, 120.9, 77.4, 77.1, 76.8, 61.3, 21.7. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 85/15, flow = 0.5 mL/min, retention time 37.3 min and 39.6 (maj) min.




(S)-5-methoxy-3-phenyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (2b): 94% yield, 85% ee(*S*), known compound^{4d}, white solid, m.p.= 120-121 °C, $[\alpha]_D^{20} = +61.4$ (c 0.52, CH₃Cl). ¹H NMR (400 MHz,




CDCl₃) δ 7.71 (d, J = 8.7 Hz, 1H), 7.38 (m, 5H), 7.03 (d, J = 6.4 Hz, 1H), 6.53 (d, J = 2.2 Hz, 1H), 5.66 (d, J = 4.1 Hz, 1H), 5.21 (s, 1H), 3.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.8, 142.5, 138.9, 129.3, 129.0, 127.6, 126.9, 122.6, 116.5, 109.2, 77.4, 77.1, 76.8, 61.2, 55.8. HPLC: Chiracel AD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 85/15, flow = 0.7 mL/min, retention time 36.7 min and 42.5(maj) min.

(S)-3-(3-(((tert-butyl)dimethylsilyloxy)methyl)phenyl)-2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide(S4):



97% yield, 89% ee(*S*), unknown compound, white solid, m.p.= 149.1-152.2 °C, [α]_D²⁰ = +105.9 (c 0.57, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.63–7.47 (m, 2H), 7.45–7.33 (m, 2H), 7.29 (t, J = 2.0 Hz, 1H), 7.23 (tt, J = 5.2, 3.0 Hz, 1H), 7.09–7.01 (m, 1H), 5.21 (s, 1H), 4.76 (s, 2H), 2.78 (s, 3H), 0.93 (s, 9H), 0.10 (d, J = 3.6 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 142.7, 138.4, 136.6, 133.0, 129.3, 129.1, 126.8, 126.8, 125.7, 125.1, 121.1, 67.0, 64.6, 27.4, 25.9, 18.4, -5.2. HRMS Calculated for C₂₁H₃₀NO₃SSi [M+H]⁺ 404.1716, found: 404.1703. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 80/20, flow = 0.8 mL/min, retention time 6.8 min (maj) and 8.5 min.

(S)-3-(3-(hydroxymethyl)phenyl)-2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (3): 87% yield, 88% ee(*S*),





known compound^{4b}, white solid, [α]_D²⁰ = +134.4 (c 0.17, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.95–7.75 (m, 1H), 7.60–7.45 (m, 2H), 7.39 (d, J = 5.6 Hz, 2H), 7.33 (s, 1H), 7.26 (m, J = 5.8, 2.6, 2.2 Hz, 1H), 7.13 – 6.98 (m, 1H), 5.21 (s, 1H), 4.68 (s, 2H), 2.76 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 142.2, 138.3, 136.9, 133.9, 133.1, 129.4, 129.4, 127.7, 127.3, 126.3, 125.1, 121.1, 77.4, 77.1, 76.8, 67.0, 64.6, 27.5. HPLC: Chiracel OD column, 220 nm, 30 °C, *n*-hexane/*i*-propanol = 70/30, flow = 0.8 mL/min, retention time 6.8 min (maj) and 8.5 min.

8. References

- (a) Ma, J.-J.; Zhang, X.; Yuan, W.; Huang, X.-Q.; Luo, S.-P.; Meggers, E. *Nat. Protoc.* **2018**, *13*, 605.
(b) Huo, H.-H.; Fu, C.; Harms, K.; Meggers, E. *J. Am. Chem. Soc.* **2014**, *136*, 2990.
- (a) Li, B.; Chen, J.; Zhang, Z.; Gridnev, I. D.; Zhang, W. *Angew. Chem. Int. Ed.* **2019**, *58*, 7329.
(b) Cramer, N.; Pham, M. V. *Chem. Eur. J.* **2016**, *22*, 2270.
- Ojha, S.; Panda, S. *Adv. Synth. Catal.* **2020**, *362*, 561.
- (a) Wang, Y.-Q.; Lu, S.-M.; Zhou, Y.-G. *J. Org. Chem.* **2007**, *72*, 3729. (b) Yu, C.-B.; Wang, D.-W.; Zhou, Y.-G. *J. Org. Chem.* **2009**, *74*, 5633. (c) Song, B.; Yu, C.-B.; Huang, W.-X.; Chen, M.-W.; Zhou, Y.-G. *Org. Lett.* **2015**, *17*, 190. (d) Song, B.; Yu, C.-B.; Ji, Y.; Chen, M.-W.; Zhou, Y.-G. *Chem. Commun.* **2017**, *53*, 8089.
- Gao, Y.; Yang, F.; Pu, D.-D.; Laishram, R. D.; Fan, R.-F.; Shen, G.-L.; Zhang, X.-X.; Chen, J.-C.; Fan, B.-M. *Eur. J. Org. Chem.* **2018**, *2018*, 6274.
- Sun, R.; Qiu, Z.-X.; Cao, G.-R.; Teng, D.-W. *Tetrahedron.* **2020**, *76*, 131201.
- Gao, Y.; Zhang, X.-X.; Laishram, R. D.; Chen, J.-C.; Li, K.-K.; Zhang, K.-Y.; Zeng, G.-Z.; Fan, B.-M. *Adv. Synth. Catal.* **2019**, *361*, 3991.
- Mao, J.-M.; Baker, D.C. *Org. Lett.* **1999**, *1*, 841.


9. Copy of NMR and HPLC for the Compounds

pdata/1




— 1.67 H₂O

¹H NMR(400 HMz, CDCl₃)




pdata/1




77.42 CDCl3
77.10 CDCl3
76.78 CDCl3

— 61.85


¹³C NMR(101 HMz, CDCl₃)




pdata/1




pdata/1




pdata/1




¹H NMR(400 HMz, CDCl₃)



pdata/1




¹³C NMR(101 HMz, CDCl₃)



pdata/1

7.82
7.81
7.80
7.79
7.77
7.76
7.75
7.74
7.73
7.72
7.71
7.70
7.69
7.68
7.67
7.66
7.65
7.64
7.63
7.62
7.61
7.60
7.59
7.58
7.57
7.56
7.55
7.54
7.53
7.52
7.51
7.50
7.49
7.48
7.47
7.46
7.45
7.44
7.43
7.42
7.41
7.40
7.39
7.38
7.37
7.36
7.35
7.34
7.33
7.32
7.31
7.30
7.29
7.28
7.27
7.26
7.25
7.24
7.23
7.22
7.21
7.20
7.19
7.18
7.17
7.16
7.15
7.14
7.13




5.69




2.36



1.28



¹H NMR(400 HMz, CDCl₃)




pdata/1

140.15
138.99
135.84
134.82
133.30
129.89
129.40
127.55
125.39
121.06


77.44 CDCl₃
77.12 CDCl₃
76.81 CDCl₃

61.17


21.20




¹³C NMR(101 HMz, CDCl₃)





pdata/1




pdata/1




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1



¹³C NMR(101 HMz, CDCl₃)



pdata/1




5.71

4.99


2.70
2.68
2.66
2.64

1.68 H₂O

1.27
1.25
1.23



¹H NMR(400 HMz, CDCl₃)



pdata/1


145.35
140.11
135.96
134.78
133.35
129.73
127.75
125.46
121.09

77.45 CDCl₃
77.13 CDCl₃
76.81 CDCl₃


61.23

28.58


15.51




¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1



¹³C NMR(101 HMz, CDCl₃)




pdata/1




7.82
7.80
7.79
7.56
7.54
7.53
7.51
7.49
7.28
7.27
7.20
7.18
7.14
-5.70
-5.32
2.63
2.61
2.59
1.63
1.61
1.59
1.57
1.51
1.41
1.37
1.35
1.34
1.32
1.30
0.96
0.94



¹H NMR(400 HMz, CDCl₃)



pdata/1



143.95
140.13
136.00
134.72
133.33
129.40
129.24
127.56
125.47
121.06

77.49 CDCl₃
77.18 CDCl₃
76.86 CDCl₃


-61.20

-35.35
-33.54


-22.39

-14.00


¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1



pdata/1



pdata/1




5.69
5.68


5.15
5.14

3.81
3.79
3.78
3.78

1.78 H2O



¹H NMR(400 HMz, CDCl₃)



pdata/1

160.12

140.29

134.97

133.29

130.71

129.40

128.99

125.42

121.05

114.59


77.41 CDCl3

77.26 CDCl3


76.78 CDCl3

60.95


55.38




¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)






¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1




pdata/1




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1




¹³C NMR(101 HMz, CDCl₃)




pdata/1




pdata/1





pdata/1




pdata/1







pdata/1




¹H NMR(400 HMz, CDCl₃)




pdata/1



¹³C NMR(101 HMz, CDCl₃)




Data file: YL-3-29-V-2022-07-12 20-39-32+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-29 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-12 20:40:20+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OJ, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
20,791	2,043	8637,59	179,45	49,31
22,451	5,065	8880,90	148,68	50,69
Sum		17518,49		




rac-1a

Data file: YL-3-29-V-2022-07-12 16-21-39+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-29 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-12 16:22:21+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OJ, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
20,559	2,397	6333,43	134,39	98,29
22,521	1,703	109,99	2,48	1,71
Sum		6443,42		




(S)-1a

Data file: YL-4-84-V-2023-04-12 08-01-12+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-4-84 **Operator:** SYSTEM
Instrument: Ic1260 **Injection date:** 2023-04-12 08:11:49+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
7.971	1.863	3391,87	204,60	49,98
9.836	0.325	3394,17	159,84	50,02
Sum		6786,04		




Data file: YL-3-84-V-2023-04-11 20-05-38+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-84 **Operator:** SYSTEM
Instrument: Ic1260 **Injection date:** 2023-04-11 20:10:03+08:00
Acq. method: BS-10-73.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
7.363	1.690	7540,80	502,23	95,41
8.979	0.287	362,37	19,10	4,59
Sum		7903,17		




Data file: YL-3-71-V-2022-11-11 18-44-11+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-71 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-11 18:45:24+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 1 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
10.835	0.333	13704.72	634.53	50.06
12.112	0.371	13673.82	568.12	49.94
Sum		27378.54		




Data file: YL-3-71-V-2022-11-11 19-03-30+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-71 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-11 19:04:16+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 1 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
10.785	1.117	485.07	22.92	3.87
12.026	0.370	12040.99	500.00	96.13
Sum		12526.05		




Data file: YL-3-62-V-2022-07-22 14-40-27+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-62 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 14:40:52+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
20,304	2,740	14254,64	357,41	49,93
23,071	4,283	14294,84	325,77	50,07
	Sum	28549,48		




Data file: YL-3-62-V-2022-07-22 15-18-48+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-62 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 15:19:24+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
20,206	2,210	721,15	18,51	3,86
22,765	4,170	17967,40	415,34	96,14
	Sum	18688,55		




Data file: YL-3-138 1-V-2022-10-15 15-08-50+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-138 1 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-15 15:09:36+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
17.970	0.651	2783.74	64.69	47.95
20.134	0.734	3022.36	61.92	52.05
Sum		5806.10		




rac-1e

Data file: YL-3-138 1-V-2022-10-15 14-26-04+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-138 1 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-15 14:39:30+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
17.534	0.708	808.79	17.35	2.60
19.624	0.804	30318.26	576.82	97.40
Sum		31127.05		




(S)-1e

Data file: YL-3-130 3-V-2022-10-14 18-10-38+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-130 3 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-14 18:10:51+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
14,077	2,357	5631,65	184,99	49,92
20,626	3,003	5649,98	133,66	50,08
Sum		11281,63		




rac-1f

Data file: YL-3-130 3-V-2022-10-14 19-10-12+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-130 3 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-14 19:10:58+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
14,950	3,483	757,76	24,59	3,53
21,448	5,057	20718,05	458,18	96,47
Sum		21475,81		




(*S*)-1f

Data file: YL-3-160-V-2022-11-07 17-04-02+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-160 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-07 17:28:24+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
44.310	5.393	7061.95	85.03	50.40
49.415	5.368	6950.82	70.28	49.60
Sum		14012.77		




Data file: YL-3-160-V-2022-11-07 14-55-46+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-160 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-07 15:10:29+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
42.413	5.093	8225.70	99.96	97.46
48.284	4.660	214.40	2.28	2.54
Sum		8440.10		




Data file: YL-3-67-V-2022-07-22 19-50-40+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-67 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 19:51:09+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
12.815	1.567	6106.52	270.73	50.07
14.394	1.928	6088.28	243.12	49.93
Sum		12194.80		




Data file: YL-3-67-V-2022-07-22 20-09-13+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-67 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 20:09:46+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
12.774	1.809	20239.24	911.15	99.59
14.948	0.607	83.67	1.90	0.41
Sum		20322.92		




Data file: YL-3-154-V-2022-10-28 15-58-42+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-154 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-28 16:01:47+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
14.175	1.599	11870.46	413.58	49.96
21.271	3.158	11890.01	247.72	50.04
	Sum	23760.47		




Data file: YL-3-154-V-2022-10-28 14-34-59+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-154 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-28 14:37:12+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
14.112	0.442	9630.80	334.42	84.34
21.193	0.692	1788.51	39.84	15.66
	Sum	11419.31		




Data file: YL-3-146-V-2022-10-29 14-50-38+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-146 **Operator:** SYSTEM
Instrument: Ic1260 **Injection date:** 2022-10-29 15:01:06+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 90/10, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
10,718	0,341	33572,10	1520,44	49,91
12,156	0,369	33688,32	1404,23	50,09
Sum		67260,42		




Data file: YL-3-159-V-2022-10-29 15-35-16+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-159 **Operator:** SYSTEM
Instrument: Ic1260 **Injection date:** 2022-10-29 15:36:15+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 90/10, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
11,085	1,674	832,20	40,32	18,86
12,519	2,987	3579,95	154,08	81,14
Sum		4412,15		




Data file: YL-3-100 1-V-2022-09-12 20-18-44+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-100 1 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-09-12 20:19:31+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
21.631	2.930	3129.98	80.16	49.42
29.951	3.448	3203.54	59.30	50.58
Sum		6333.52		




Data file: YL-3-100 2-V-2022-09-12 19-39-54+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-100 2 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-09-12 19:40:47+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
22.084	0.586	470.64	12.28	9.46
30.509	0.850	4503.60	82.39	90.54
Sum		4974.23		




Data file: YL-3-154-V-2022-10-27 20-07-44+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-154 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-27 20:08:15+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
25.776	3.195	5052.84	96.11	49.45
38.380	6.272	5165.41	61.85	50.55
Sum		10218.25		




Data file: YL-3-154-V-2022-10-27 19-19-18+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-154 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-27 19:19:56+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
24.892	0.829	3032.34	55.61	94.29
38.242	1.177	183.76	1.82	5.71
Sum		3216.10		




Data file: YL-3-130 3-V-2022-10-14 15-58-40+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-130 3 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-14 15:59:25+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
27.409	3.752	12874.97	247.61	50.08
31.185	0.929	12833.41	210.04	49.92
Sum		25708.37		




Data file: YL-3-130 3-V-2022-10-12 20-10-29+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-130 3 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-12 20:11:08+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
26.278	4.130	9528.35	194.10	94.38
30.811	3.202	567.11	7.96	5.62
Sum		10095.47		




Data file: YL-3-146-V-2022-10-31 14-16-57+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-146 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-31 14:18:08+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
23.156	0.681	7402.57	164.71	49.99
31.183	0.913	7405.46	124.19	50.01
Sum		14808.03		




Data file: YL-3-146-V-2022-10-30 20-08-03+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-146 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-30 20:19:44+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
23.545	2.047	374.78	8.94	4.33
31.337	3.917	8276.09	141.36	95.67
Sum		8650.88		




Data file: YL-3-64-V-2022-07-22 15-51-31+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-64 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 15:52:06+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
12.783	0,351	6197,60	271,04	49,73
19.162	2.688	6263.72	172.62	50.27
Sum		12461.32		




Data file: YL-3-64-V-2022-07-22 16-15-59+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-64 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 16:16:35+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
12.769	2,973	8658,93	375,74	96,05
19.317	2.457	355.83	9.67	3.95
Sum		9014.76		




Data file: YL-3-65-V-2022-07-22 17-04-17+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-65 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 17:04:28+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A, Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
16.217	3,260	6561,78	218,24	50,18
20.538	3.738	6514.63	166.57	49.82
Sum		13076.41		




Data file: YL-3-65-V-2022-07-22 17-31-14+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-65 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 17:31:48+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A, Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
16,113	2,995	9847,51	322,07	97,59
20.639	2.500	242.71	6.08	2.41
Sum		10090.21		




Data file: YL-3-65-V-2022-07-22 11-07-45+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-65 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 11:08:34+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OJ, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
24.835	3.927	9216.79	138,16	50,47
28.895	5.948	9044.46	99,81	49,53
Sum		18261.25		




Data file: YL-3-65-V-2022-07-22 13-15-39+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-65 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-07-22 13:16:48+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OJ, Hexane/i-PrOH = 70/30, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
25.011	4.713	4575,66	67,88	94,02
29.659	3.498	290,86	3,18	5,98
Sum		4866,53		




Data file: YL-3-160-V-2022-10-31 16-45-04+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-160 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-31 16:45:58+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
30,811	0,881	6604,28	114,48	51,61
38,153	1,023	6191,66	91,12	48,39
Sum		12795,94		




rac-1r

Data file: YL-3-160-V-2022-10-31 15-58-24+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-160 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-31 15:58:55+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,6 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
30,865	4,030	8348,00	145,06	96,06
38,369	3,078	342,05	4,85	3,94
Sum		8690,05		




(*S*)-1r

Data file: YL-3-130-V-2022-10-10 19-47-45+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-130 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-10 19:49:26+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
30.209	4.912	6809.42	113.75	49.69
38.196	4.825	6894.92	92.48	50.31
Sum		13704.34		




rac-1s

Data file: YL-3-130-V-2022-10-10 18-58-20+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-130 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-10-10 18:59:07+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 80/20, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
30.430	1.723	247.45	4.90	2.05
38.693	5.449	11822.36	154.51	97.95
Sum		12069.81		




(S)-1s

Data file: YL-3-174-V-2022-11-22 16-31-36+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-174 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-22 16:34:25+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
37,743	5,040	7194,85	83,65	50,10
48,976	1,809	7166,96	58,70	49,90
Sum		14361,81		




Data file: YL-3-174-V-2022-11-22 15-18-00+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-174 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-22 15:28:04+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
38,042	6,650	5153,09	58,45	94,20
49,921	1,317	317,11	2,82	5,80
Sum		5470,20		




Data file: YL-5-9-V-2023-06-28 17-35-54+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-5-9 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2023-06-28 17:36:32+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 85/15, 0,5 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
37.480	0,940	13904,39	224,30	48,91
39.876	1.026	14526.94	214.72	51.09
Sum		28431.33		




rac-2a

Data file: YL-5-9-V-2023-06-28 16-45-40+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-5-9 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2023-06-28 16:46:16+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 85/15, 0,5 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
37.325	2,503	586.82	9,57	3,82
39.644	5.419	14756.18	215.79	96.18
Sum		15343.00		




(S)-2a

Data file: YL-5-10-V-2023-06-29 13-17-45+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-5-10 **Operator:** SYSTEM
Instrument: Ic1260 **Injection date:** 2023-06-29 13:30:35+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 85/15, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
36.778	1.034	2711.72	39.56	50.08
42.716	1.196	2703.13	34.09	49.92
Sum		5414.85		




rac-2b

Data file: YL-5-10-V-2023-06-29 14-20-05+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-5-10 **Operator:** SYSTEM
Instrument: Ic1260 **Injection date:** 2023-06-29 14:22:32+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: AD, Hexane/i-PrOH = 85/15, 0,7 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
36.733	3.578	1137.23	16.74	7.54
42.542	4.836	13938.38	178.81	92.46
Sum		15075.61		




(*S*)-2b

Data file: YL-3-29-V-2022-11-12 16-34-28+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-29 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-12 16:36:30+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 80/20, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
27,565	2,855	410,97	7,57	1,56
32,872	1,030	25910,82	382,78	98,44
Sum		26321,79		




Data file: YL-3-29-V-2022-11-11 21-05-00+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-3-29 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2022-11-11 21:05:27+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 80/20, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
26,244	3,772	9032,54	176,38	92,94
31,897	4,153	686,50	11,09	7,06
Sum		9719,04		




Data file: YL-4-88-V-2023-04-19 08-18-18+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-4-88 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2023-04-19 08:24:49+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 80/20, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
6,772	1,330	4607,34	380,08	50,06
8,419	0,236	4596,92	294,50	49,94
Sum		9204,26		




Data file: YL-4-88-V-2023-04-19 08-40-56+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-4-88 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2023-04-19 08:41:09+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 80/20, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
6,799	1,447	5944,54	477,46	94,57
8,532	0,241	341,58	21,60	5,43
Sum		6286,11		




Data file: YL-4-127-V-2023-05-03 17-00-47+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-4-127 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2023-05-03 17:02:43+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm




Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
10.276	0,370	7300,08	298,58	50,08
12.828	0,481	7276,99	229,83	49,92
Sum		14577,07		



Data file: YL-4-127-V-2023-05-04 15-21-32+08-00.dx
Sequence Name: SingleSample **Project Name:** 1260
Sample name: YL-4-127 **Operator:** SYSTEM
Instrument: lc1260 **Injection date:** 2023-05-04 15:24:27+08:00
Acq. method: YL-1-57.amx **Type:** Sample
Processing method: GC_LC Area Percent_DefaultMethod.pmx
Sample Info: OD, Hexane/i-PrOH = 70/30, 0,8 mL/min, 30 oC, 220 nm



Signal: VWD1A,Wavelength=220 nm

RT [min]	Peak Width Base	Area	Height	Area%
10.486	0,394	16649,56	646,16	94,14
13.403	0,507	1035,93	31,16	5,86
Sum		17685,50		

